


Healthcare | Small Cap
Jagsonpal Pharmaceuticals Ltd. presents a very strong financial profile, characterized by exceptional health in several key areas. The company has an outstanding ability to cover its short-term bills and is virtually debt-free, indicating a very low-risk financial structure. It demonstrates excellent profitability, efficiently converting sales into high profits, and has shown robust growth in both sales and earnings. This points to a healthy, well-managed core business. However, while the company's operations are very strong, the direct financial returns to shareholders, such as earnings and book value per share, are less impressive and appear average or weak. The future outlook is positive due to its solid foundation, but the value passed on to individual shareholders presents a different picture compared to its operational excellence.
Jagsonpal Pharmaceuticals Ltd. presents a very strong financial profile, characterized by exceptional health in several key areas. The company has an outstanding ability to cover its short-term bills and is virtually debt-free, indicating a very low-risk financial structure. It demonstrates excellent profitability, efficiently converting sales into high profits, and has shown robust growth in both sales and earnings. This points to a healthy, well-managed core business. However, while the company's operations are very strong, the direct financial returns to shareholders, such as earnings and book value per share, are less impressive and appear average or weak. The future outlook is positive due to its solid foundation, but the value passed on to individual shareholders presents a different picture compared to its operational excellence.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
36.26
Industry Median
32.38
Small Cap Median
29.54
P/E RATIO
36.20
P/B RATIO
5.65
Industry Median
3.38
Small Cap Median
2.89
P/S RATIO
5.44
Industry Median
3.65
Small Cap Median
2.73
Others
PEG RATIO
1.71
EV/EBITDA RATIO
21.53
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹232.77 as on Jul 11, 2026.
The company's growth profile is outstanding across the board. It has demonstrated very strong performance in increasing its revenue, operating profit, and bottom-line income over the analysis period. This growth is also reflected in the significant expansion of its asset base. Such consistent and high growth in all key financial areas is a very positive indicator, suggesting strong market demand, effective strategy, and a promising upward trajectory for the business.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 15.96 | 8.72 | -11.81 | 28.71 | 6.69 |
| Operating Profit Growth Rate | 36.84 | 30.77 | -32.35 | 121.74 | 13.73 |
| Earnings Per Share (EPS) Growth | 10.77 | 41.67 | -16.67 | 145.29 | -22.9 |
| Asset Growth Rate | 0 | 18.9 | 11.28 | 28.11 | 14.03 |
| Net Income Growth Rate | 11.76 | 42.11 | -18.52 | 150 | -21.82 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 36.20 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 76.34 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 26.36 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 14.03 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 40.99 | Overvalued | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 17.51 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 60.18 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 32.38 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 23.57 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 51.66 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 31.96 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -277.51 | Neutral | 187.00 | -1.50 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤3rd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Annual Report⬤2nd Jul 26
Annual Report 2025-26
UNDEFINED SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT